SEER

Business Context and Reporting Period

Company: Seer, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2020
Business Overview: Seer is an early-stage life sciences technology company developing the Proteograph Product Suite, an integrated solution (consumables, automation instrument, and software) designed to enable unbiased, deep, and large-scale proteomic analysis. The company utilizes proprietary engineered nanoparticle (NP) technology to overcome limitations in current proteomics methods. As of the reporting date, the company was in the "collaboration phase" of its three-phase commercial launch plan, having delivered initial instruments to key opinion leaders but not yet achieving broad commercial availability.

Key Financial Metrics

Note: Revenue consists of research collaboration and grant funding. The company has not generated revenue from product sales.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 466% year-over-year, driven by a Small Business Innovation Research (SBIR) grant from the NIH and the completion of a research collaboration study.
• Expense Surge: Operating expenses more than doubled (102% increase). General and Administrative (G&A) expenses rose 234% primarily due to stock-based compensation ($5.3 million increase), personnel growth, and costs associated with the initial public offering (IPO) and the PrognomIQ spin-out. R&D expenses increased 53% due to expanded product development efforts.
• Liquidity Position: Cash and investments increased significantly from $86.0 million to $431.9 million. This was driven by the December 2020 IPO (net proceeds of $183.9 million), a concurrent private placement (net proceeds of $130.3 million), and a Series D-1 preferred stock issuance (net proceeds of $54.9 million).
• Capital Structure: Immediately prior to the IPO, all outstanding convertible preferred stock converted into Class A common stock. The company completed a reverse stock split in November 2020.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Commercialization Plan

Management expects to continue incurring significant losses and negative cash flows from operations for the foreseeable future. The company plans to commercialize the Proteograph Product Suite via a three-phase plan:

1. Collaboration Phase (Current): Working with key opinion leaders to validate the product.
2. Early Access Limited Release (Expected 2021): Selling to select sites to demonstrate value.
3. Broad Commercial Availability (Expected Early 2022): Full market launch.

Material Risks and Contingencies

• Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel for segregation of duties, lack of formalized reconciliation processes, and insufficient technical expertise for complex transactions. Remediation efforts are underway but were not complete as of December 31, 2020.
• Profitability: The company has a history of net losses and an accumulated deficit of $55.4 million. There is no assurance it will achieve profitability.
• COVID-19 Impact: The pandemic has caused supply chain delays (specifically for the SP100 automation instrument from Hamilton Company) and restricted laboratory access, potentially delaying commercialization and customer training.
• Regulatory Uncertainty: While products are currently labeled "Research Use Only" (RUO), there is a risk that the FDA could deem them medical devices requiring clearance or approval if used for diagnostic purposes by customers.
• PrognomIQ Spin-out: In August 2020, the company spun out PrognomIQ, Inc. to focus on diagnostics. Seer retains approximately 19% ownership. The carrying value of the investment was reduced to zero in 2020 due to PrognomIQ's losses.

Investor Verification Checklist

• Commercialization Timeline: Verify progress in transitioning from the collaboration phase to the early access limited release phase and the timing of the expected 2022 broad launch.
• Internal Control Remediation: Monitor the company's progress in hiring accounting personnel and implementing controls to remediate the identified material weaknesses.
• Supply Chain Stability: Assess the status of the contract manufacturing agreement with Hamilton Company and any ongoing lead time delays for the SP100 instrument.
• Burn Rate and Runway: Evaluate the rate of cash consumption against the $431.9 million cash balance to confirm the sufficiency of capital for the next 12+ months.
• Revenue Recognition: Confirm the nature of future revenue streams, as current revenue is derived from grants and collaborations rather than product sales.